Nectar Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
For the nine months, sales was INR 14,141.48 million compared to INR 13,005.34 million a year ago. Revenue was INR 12,558.19 million compared to INR 11,601.1 million a year ago. Net income was INR 44.03 million compared to net loss of INR 278.6 million a year ago. Basic earnings per share from continuing operations was INR 0.2 compared to basic loss per share from continuing operations of INR 1.24 a year ago. Diluted earnings per share from continuing operations was INR 0.2 compared to diluted loss per share from continuing operations of INR 1.24 a year ago.